Clinical trial Recruiting at 4 sites Interventional Ages 18 to 40 Women only

Renal denervation for women with hypertension planning pregnancy

Official title: Renal Denervation in Hypertensive Women Planning to Become Pregnant

Run by University Hospital, Bordeaux · NCT05563337 · Data updated 2026-11-12

This study tests if a procedure called renal denervation can help women with high blood pressure who are planning to get pregnant manage their condition better.

More Arterial Hypertension trials

Quick facts

Study typeInterventional
Ages18 Years to 40 Years
SexWomen only
Enrollment80 (estimated)
SponsorUniversity Hospital, Bordeaux
Academic / other
Locations6 sites (Bordeaux and 5 other locations)
StatusRecruiting
StartedJanuary 31, 2023
Main results expectedMay 18, 2025
Study endsNovember 30, 2028
Registry record updatedAugust 31, 2023
Trial IDNCT05563337 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are women aged 18 to 40 with essential hypertension who are not currently pregnant but plan to conceive within the next two years.

Probably not a fit

Patients who are male, under 18 or over 40 years old, or those with orthostatic hypotension may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of renal denervation on women with essential hypertension who are planning to become pregnant. Participants will undergo arteriography and be randomized into either a renal denervation group or a control group without the procedure. Blood pressure will be monitored through home measurements and ambulatory blood pressure monitoring (ABPM) before and during pregnancy. The study aims to assess the safety and efficacy of renal denervation in managing hypertension in this specific population.

Why it matters

Potential benefit: If successful, this approach could provide a safer and more effective way to manage hypertension in women planning to become pregnant.

How similar studies have gone: While renal denervation has shown efficacy in resistant hypertension, its application in pregnant women is novel and has not been extensively tested in previous studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* ≥ 18 years and ≤ 40 years
* Free, informed, written consent signed by the participant and the investigating physician (no later than the day of inclusion and before any examination required by the research)
* Not pregnant but planning to be pregnant in the near future (\<2 years)
* Patient using effective contraception, preferably micro-progestational, during the screening phase and the two-month post-procedure follow-up
* Essential hypertension confirmed and documented by a previous complete search
* Hypertension treated by 0-2 antihypertensive treatment(s) in a stable manner for at least 4 weeks and whose clinical BP measured in the sitting position during consultation is ≤ 180/110mmHg at the selection visit (D0),
* Person able to understand and agree to follow all study procedures
* Person who is affiliated or beneficiary of a social security plan

Non-Inclusion Criteria:

* Males of any age
* Females whose age is \<18 years or \>40
* Orthostatic hypotension
* Hypertension from secondary causes (other than sleep apnea)
* Documented contraindication or proven severe allergy to iodinated contrast
* Contraindication to use anticoagulants
* Renal insufficiency with GFR estimated at \< 60ml/min/1.73m²
* Antihypertensive treatment with more than two active ingredients
* Type 1 diabetes or uncontrolled type II diabetes (plasma HbA1c level ≥ 9%)
* History of chronic inflammatory bowel disease such as Crohn's disease or ulcerative colitis
* Brachial circumference \> 40 cm
* Any history of a cerebrovascular event (stroke, transient ischemic attack)
* Any history of a serious cardiovascular event (myocardial infarction, acute heart failure requiring hospitalization, coronary artery bypass surgery)
* Proven and confirmed episodes of stable or unstable angina in the 12 months preceding consent
* Proven history of persistent or permanent atrial fibrillation
* Presence of an active implantable medical device (e.g. neuromodulator/spinal modulator, baroreflex stimulator, ...)
* Oxygen therapy or permanent ventilation other than CPAP for sleep apnea
* Primary pulmonary hypertension
* Limited life expectancy (\< 1 year)
* Unresolved history of drug or alcohol abuse
* Not have sufficient ability to understand or follow instructions
* In the investigator's opinion she is unlikely to be willing or able to comply with the requirements of the study protocol or participation in the study will involve confounding factors in the analysis of the data
* Participation in another trial of an investigational drug or device (participation in a non-interventional study is tolerated)
* Pregnant or nursing mother
* Person unable to give informed consent
* Person deprived of liberty by judicial or administrative decision
* Adults under legal protection

Exclusion Criteria:

* BP ≤ 135/85 mmHg and ≥ 160/100 mmHg (ABPM) after 4 weeks washout/run-in period.
* Renal arterial anatomy not compatible with renal denervation confirmed by a good quality renal artery angioscan performed within one year prior to consent.
* Patient without at least one artery on each side that can be treated with 2 or more ablations,
* Renal artery anatomy:

  * Main renal artery diameter \< 3.0 mm and \> 8 mm
  * Main renal artery length \< 20 mm
  * A single functioning kidney (low differentiation or small kidney)
  * Kidney tumors presence
  * Renal arterial aneurysm presence
  * Pre-existing renal stent or history of renal artery angioplasty
  * Pre-existing aortic stent or history of aortic aneurysm
  * Prior renal denervation procedure
  * Fibromuscular dysplasia of the renal arteries
  * Presence of renal artery stenosis of any origin ≥ 30%
  * Presence of iliac/femoral artery calcification or stenosis precluding insertion of the Paradise Catheter
  * Infection within 7 days of the procedure

Where it's running

  • CHU de Bordeaux - Hôpital Saint-André
    Bordeaux, France
    Recruiting
  • CHU Grenoble-Alpes
    Grenoble, France
    Recruiting
  • CHU de Nantes - Hôpital Laennec
    Nantes, France
    Recruiting
  • APHP - Hôpital Européen Georges-Pompidou
    Paris, France
    Recruiting
  • CHRU de LILLE - Hôpital Cardiologique
    Lille, France
    Not yet recruiting
  • CHU de TOULOUSE - Hôpital Rangueil
    Toulouse, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.